| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteoarthritis, Knee | 117 | 2024 | 1251 | 20.570 |
Why?
|
| Arthroplasty, Replacement, Knee | 61 | 2023 | 1401 | 8.710 |
Why?
|
| Cost-Benefit Analysis | 95 | 2024 | 5532 | 3.990 |
Why?
|
| HIV Infections | 164 | 2024 | 17492 | 3.950 |
Why?
|
| Osteoarthritis | 21 | 2021 | 1070 | 3.400 |
Why?
|
| Arthroplasty, Replacement, Hip | 39 | 2023 | 1418 | 3.260 |
Why?
|
| Knee Joint | 28 | 2023 | 1683 | 2.990 |
Why?
|
| Anti-HIV Agents | 67 | 2020 | 4563 | 2.750 |
Why?
|
| Arthralgia | 13 | 2022 | 462 | 2.590 |
Why?
|
| Quality-Adjusted Life Years | 37 | 2024 | 1734 | 2.520 |
Why?
|
| Knee Injuries | 12 | 2022 | 495 | 2.040 |
Why?
|
| Pain | 29 | 2024 | 5096 | 2.000 |
Why?
|
| Health Care Costs | 31 | 2024 | 3266 | 1.910 |
Why?
|
| Pain Measurement | 31 | 2024 | 3577 | 1.880 |
Why?
|
| CD4 Lymphocyte Count | 68 | 2020 | 2589 | 1.840 |
Why?
|
| Osteoarthritis, Hip | 10 | 2023 | 409 | 1.680 |
Why?
|
| Antiretroviral Therapy, Highly Active | 35 | 2020 | 1898 | 1.670 |
Why?
|
| Exercise | 11 | 2020 | 5940 | 1.670 |
Why?
|
| Exercise Therapy | 9 | 2024 | 941 | 1.630 |
Why?
|
| Menisci, Tibial | 13 | 2022 | 267 | 1.610 |
Why?
|
| South Africa | 55 | 2020 | 1870 | 1.610 |
Why?
|
| AIDS-Related Opportunistic Infections | 27 | 2015 | 664 | 1.590 |
Why?
|
| Computer Simulation | 40 | 2022 | 6278 | 1.560 |
Why?
|
| Knee Prosthesis | 6 | 2016 | 395 | 1.510 |
Why?
|
| Physical Therapy Modalities | 7 | 2022 | 533 | 1.410 |
Why?
|
| Obesity, Morbid | 4 | 2023 | 1309 | 1.380 |
Why?
|
| Male | 323 | 2024 | 364761 | 1.370 |
Why?
|
| Anti-Retroviral Agents | 22 | 2018 | 1792 | 1.360 |
Why?
|
| Antirheumatic Agents | 9 | 2021 | 1374 | 1.360 |
Why?
|
| Life Expectancy | 33 | 2023 | 1249 | 1.320 |
Why?
|
| Female | 320 | 2024 | 396926 | 1.290 |
Why?
|
| Humans | 469 | 2024 | 768369 | 1.280 |
Why?
|
| Mobile Health Units | 4 | 2019 | 93 | 1.260 |
Why?
|
| Orthopedics | 13 | 2017 | 906 | 1.240 |
Why?
|
| Orthopedic Procedures | 8 | 2024 | 1280 | 1.220 |
Why?
|
| Arthritis, Rheumatoid | 19 | 2023 | 3762 | 1.220 |
Why?
|
| Middle Aged | 202 | 2024 | 223406 | 1.200 |
Why?
|
| Aged | 167 | 2024 | 171514 | 1.170 |
Why?
|
| Arthroscopy | 13 | 2022 | 971 | 1.160 |
Why?
|
| Medicare | 27 | 2024 | 6880 | 1.150 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 8 | 2023 | 2279 | 1.140 |
Why?
|
| Analgesics, Opioid | 13 | 2024 | 3837 | 1.120 |
Why?
|
| Tuberculosis | 11 | 2019 | 2029 | 1.120 |
Why?
|
| Mass Screening | 28 | 2020 | 5455 | 1.110 |
Why?
|
| Obesity | 17 | 2024 | 13065 | 1.080 |
Why?
|
| Health Promotion | 5 | 2019 | 2215 | 1.080 |
Why?
|
| Models, Economic | 13 | 2019 | 717 | 1.080 |
Why?
|
| Pain, Postoperative | 10 | 2024 | 1763 | 1.020 |
Why?
|
| Occupational Health | 5 | 2019 | 814 | 1.000 |
Why?
|
| Lost to Follow-Up | 5 | 2020 | 123 | 0.950 |
Why?
|
| Range of Motion, Articular | 8 | 2019 | 1599 | 0.930 |
Why?
|
| Gastric Bypass | 2 | 2023 | 829 | 0.910 |
Why?
|
| Synovitis | 8 | 2023 | 217 | 0.900 |
Why?
|
| Adult | 192 | 2024 | 223528 | 0.900 |
Why?
|
| United States | 94 | 2024 | 73120 | 0.900 |
Why?
|
| Health Services | 4 | 2021 | 756 | 0.890 |
Why?
|
| Drug Costs | 14 | 2018 | 1196 | 0.870 |
Why?
|
| Randomized Controlled Trials as Topic | 18 | 2022 | 10358 | 0.870 |
Why?
|
| Disability Evaluation | 8 | 2024 | 1839 | 0.840 |
Why?
|
| Hospitals | 17 | 2017 | 3906 | 0.840 |
Why?
|
| Cost of Illness | 8 | 2022 | 1960 | 0.830 |
Why?
|
| Choice Behavior | 4 | 2011 | 846 | 0.820 |
Why?
|
| Prosthesis Failure | 6 | 2015 | 1208 | 0.810 |
Why?
|
| Arthrography | 2 | 2021 | 150 | 0.800 |
Why?
|
| Treatment Outcome | 77 | 2024 | 65408 | 0.800 |
Why?
|
| Weight Loss | 8 | 2024 | 2710 | 0.790 |
Why?
|
| Workplace | 2 | 2019 | 872 | 0.780 |
Why?
|
| Viral Load | 18 | 2018 | 3374 | 0.780 |
Why?
|
| Rheumatic Diseases | 7 | 2024 | 664 | 0.770 |
Why?
|
| Patient Compliance | 10 | 2018 | 2696 | 0.770 |
Why?
|
| Upper Extremity | 4 | 2023 | 683 | 0.750 |
Why?
|
| Back Pain | 3 | 2020 | 547 | 0.730 |
Why?
|
| Health Resources | 9 | 2019 | 950 | 0.730 |
Why?
|
| Activities of Daily Living | 5 | 2018 | 2433 | 0.720 |
Why?
|
| Catastrophization | 4 | 2020 | 349 | 0.710 |
Why?
|
| AIDS Serodiagnosis | 12 | 2013 | 220 | 0.710 |
Why?
|
| Cartilage, Articular | 11 | 2022 | 1103 | 0.710 |
Why?
|
| Aged, 80 and over | 62 | 2024 | 59679 | 0.690 |
Why?
|
| Recovery of Function | 13 | 2024 | 2994 | 0.680 |
Why?
|
| Postoperative Care | 3 | 2016 | 1481 | 0.660 |
Why?
|
| Practice Guidelines as Topic | 11 | 2020 | 7449 | 0.650 |
Why?
|
| Tramadol | 2 | 2016 | 63 | 0.650 |
Why?
|
| Rheumatology | 8 | 2018 | 619 | 0.650 |
Why?
|
| Postoperative Complications | 22 | 2021 | 15879 | 0.640 |
Why?
|
| Patient Selection | 9 | 2023 | 4266 | 0.630 |
Why?
|
| HIV-1 | 25 | 2020 | 6909 | 0.630 |
Why?
|
| Communicable Disease Control | 3 | 2020 | 857 | 0.620 |
Why?
|
| Ambulatory Care Facilities | 8 | 2020 | 941 | 0.620 |
Why?
|
| Self Report | 10 | 2024 | 3771 | 0.610 |
Why?
|
| Cohort Studies | 67 | 2020 | 41782 | 0.610 |
Why?
|
| Clubfoot | 1 | 2019 | 87 | 0.600 |
Why?
|
| Reoperation | 15 | 2015 | 4342 | 0.600 |
Why?
|
| Quality of Life | 21 | 2024 | 13497 | 0.600 |
Why?
|
| Musculoskeletal Diseases | 5 | 2024 | 601 | 0.600 |
Why?
|
| Demography | 4 | 2017 | 1643 | 0.590 |
Why?
|
| Social Class | 7 | 2015 | 2000 | 0.570 |
Why?
|
| Research Design | 15 | 2019 | 6217 | 0.560 |
Why?
|
| Patient Satisfaction | 13 | 2017 | 3484 | 0.550 |
Why?
|
| Prevalence | 32 | 2022 | 15879 | 0.550 |
Why?
|
| Self-Assessment | 2 | 2009 | 402 | 0.550 |
Why?
|
| Caloric Restriction | 1 | 2019 | 300 | 0.550 |
Why?
|
| Medicare Part A | 2 | 2014 | 40 | 0.540 |
Why?
|
| Disease Progression | 33 | 2022 | 13643 | 0.540 |
Why?
|
| Insurance Claim Reporting | 2 | 2010 | 166 | 0.540 |
Why?
|
| Research Report | 2 | 2020 | 369 | 0.520 |
Why?
|
| Mobility Limitation | 2 | 2018 | 409 | 0.520 |
Why?
|
| Health Knowledge, Attitudes, Practice | 9 | 2022 | 4049 | 0.520 |
Why?
|
| Patient Acceptance of Health Care | 14 | 2024 | 3237 | 0.520 |
Why?
|
| HIV | 13 | 2023 | 1587 | 0.520 |
Why?
|
| Prescription Fees | 1 | 2017 | 153 | 0.520 |
Why?
|
| Neuralgia | 1 | 2022 | 620 | 0.510 |
Why?
|
| Comprehensive Health Care | 1 | 2016 | 123 | 0.510 |
Why?
|
| Absenteeism | 1 | 2017 | 247 | 0.510 |
Why?
|
| Sensitivity and Specificity | 32 | 2019 | 14725 | 0.500 |
Why?
|
| Oxycodone | 1 | 2016 | 142 | 0.500 |
Why?
|
| Fracture Fixation | 1 | 2018 | 371 | 0.500 |
Why?
|
| Universities | 1 | 2020 | 1007 | 0.490 |
Why?
|
| Drug Resistance, Viral | 10 | 2015 | 868 | 0.490 |
Why?
|
| Spinal Neoplasms | 5 | 2021 | 715 | 0.490 |
Why?
|
| Preoperative Period | 2 | 2020 | 564 | 0.490 |
Why?
|
| Viscosupplements | 1 | 2015 | 21 | 0.490 |
Why?
|
| Actigraphy | 1 | 2019 | 526 | 0.480 |
Why?
|
| Comorbidity | 17 | 2018 | 10601 | 0.480 |
Why?
|
| Medication Adherence | 11 | 2020 | 2190 | 0.470 |
Why?
|
| Financing, Personal | 2 | 2014 | 310 | 0.470 |
Why?
|
| Nerve Growth Factor | 1 | 2015 | 157 | 0.470 |
Why?
|
| Models, Statistical | 9 | 2017 | 5103 | 0.470 |
Why?
|
| Independent Living | 1 | 2019 | 580 | 0.470 |
Why?
|
| Proprioception | 1 | 2015 | 134 | 0.470 |
Why?
|
| Risk Factors | 53 | 2023 | 74915 | 0.460 |
Why?
|
| Hospital Bed Capacity | 2 | 2019 | 206 | 0.460 |
Why?
|
| Health Services Accessibility | 8 | 2019 | 5508 | 0.450 |
Why?
|
| Mycobacterium tuberculosis | 5 | 2019 | 1931 | 0.450 |
Why?
|
| Multivariate Analysis | 21 | 2019 | 12096 | 0.450 |
Why?
|
| Muscle Strength | 1 | 2018 | 641 | 0.450 |
Why?
|
| Models, Biological | 20 | 2020 | 9505 | 0.440 |
Why?
|
| Knee | 2 | 2016 | 279 | 0.440 |
Why?
|
| Health Status | 5 | 2011 | 4096 | 0.440 |
Why?
|
| Periprosthetic Fractures | 1 | 2014 | 60 | 0.440 |
Why?
|
| Analgesics | 1 | 2020 | 1070 | 0.440 |
Why?
|
| Arthroplasty, Replacement | 2 | 2014 | 310 | 0.440 |
Why?
|
| Venous Thromboembolism | 3 | 2019 | 1881 | 0.440 |
Why?
|
| Clinical Trials as Topic | 15 | 2015 | 8051 | 0.430 |
Why?
|
| Health Surveys | 6 | 2016 | 4056 | 0.430 |
Why?
|
| Geographic Information Systems | 1 | 2015 | 283 | 0.430 |
Why?
|
| Medically Underserved Area | 1 | 2015 | 266 | 0.430 |
Why?
|
| Risk Reduction Behavior | 2 | 2019 | 1120 | 0.430 |
Why?
|
| Anterior Cruciate Ligament | 2 | 2015 | 423 | 0.420 |
Why?
|
| Medical History Taking | 1 | 2017 | 776 | 0.420 |
Why?
|
| Prosthesis Fitting | 1 | 2013 | 75 | 0.420 |
Why?
|
| Anticoagulants | 4 | 2020 | 4835 | 0.420 |
Why?
|
| Disease Management | 4 | 2018 | 2533 | 0.410 |
Why?
|
| Drugs, Generic | 1 | 2018 | 454 | 0.410 |
Why?
|
| Joint Prosthesis | 1 | 2014 | 251 | 0.410 |
Why?
|
| Osteoporotic Fractures | 2 | 2016 | 417 | 0.400 |
Why?
|
| Time Factors | 32 | 2024 | 40271 | 0.390 |
Why?
|
| Point-of-Care Systems | 5 | 2015 | 1227 | 0.390 |
Why?
|
| Radius Fractures | 1 | 2018 | 514 | 0.390 |
Why?
|
| Magnetic Resonance Imaging | 28 | 2023 | 36840 | 0.390 |
Why?
|
| Osteophyte | 4 | 2022 | 44 | 0.390 |
Why?
|
| Fractures, Bone | 5 | 2019 | 2063 | 0.390 |
Why?
|
| Postoperative Period | 5 | 2020 | 1833 | 0.390 |
Why?
|
| Injections, Intra-Articular | 3 | 2022 | 288 | 0.390 |
Why?
|
| Counseling | 7 | 2015 | 1548 | 0.380 |
Why?
|
| Age Distribution | 8 | 2016 | 2881 | 0.380 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2015 | 371 | 0.380 |
Why?
|
| Boston | 15 | 2024 | 9359 | 0.380 |
Why?
|
| HIV Protease Inhibitors | 5 | 2013 | 432 | 0.370 |
Why?
|
| Biomedical Research | 5 | 2020 | 3463 | 0.370 |
Why?
|
| Cote d'Ivoire | 10 | 2011 | 65 | 0.370 |
Why?
|
| Age Factors | 21 | 2019 | 18477 | 0.370 |
Why?
|
| Delayed-Action Preparations | 1 | 2015 | 969 | 0.370 |
Why?
|
| Delphi Technique | 4 | 2024 | 879 | 0.360 |
Why?
|
| Laparoscopy | 1 | 2022 | 2056 | 0.360 |
Why?
|
| Homosexuality, Male | 8 | 2024 | 1343 | 0.360 |
Why?
|
| Physical Examination | 1 | 2017 | 1262 | 0.360 |
Why?
|
| Perception | 1 | 2017 | 1207 | 0.360 |
Why?
|
| Therapeutic Equipoise | 1 | 2010 | 29 | 0.360 |
Why?
|
| Thrombolytic Therapy | 1 | 2019 | 2058 | 0.360 |
Why?
|
| Cost Sharing | 1 | 2014 | 409 | 0.360 |
Why?
|
| Monte Carlo Method | 7 | 2019 | 1262 | 0.350 |
Why?
|
| Risk-Taking | 7 | 2013 | 1041 | 0.350 |
Why?
|
| Continuity of Patient Care | 7 | 2017 | 1076 | 0.350 |
Why?
|
| Program Evaluation | 8 | 2018 | 2508 | 0.350 |
Why?
|
| Models, Theoretical | 15 | 2020 | 3590 | 0.350 |
Why?
|
| Patient Education as Topic | 4 | 2017 | 2339 | 0.350 |
Why?
|
| Emergency Service, Hospital | 8 | 2013 | 7955 | 0.350 |
Why?
|
| Severity of Illness Index | 19 | 2024 | 15965 | 0.350 |
Why?
|
| Bone Marrow Diseases | 4 | 2016 | 234 | 0.340 |
Why?
|
| Motivation | 5 | 2019 | 2034 | 0.340 |
Why?
|
| Emergency Medical Services | 4 | 2024 | 1947 | 0.340 |
Why?
|
| Opioid-Related Disorders | 2 | 2022 | 2188 | 0.340 |
Why?
|
| Device Approval | 1 | 2011 | 164 | 0.340 |
Why?
|
| Incidence | 22 | 2021 | 21552 | 0.330 |
Why?
|
| Carpal Tunnel Syndrome | 4 | 2014 | 304 | 0.330 |
Why?
|
| Overweight | 6 | 2024 | 2428 | 0.320 |
Why?
|
| Cities | 1 | 2011 | 545 | 0.320 |
Why?
|
| Depression | 4 | 2024 | 8235 | 0.320 |
Why?
|
| Delivery of Health Care | 9 | 2020 | 5367 | 0.320 |
Why?
|
| Patient Preference | 5 | 2022 | 948 | 0.320 |
Why?
|
| Muscular Diseases | 1 | 2013 | 555 | 0.310 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2015 | 1891 | 0.310 |
Why?
|
| Ambulatory Care | 4 | 2011 | 2780 | 0.310 |
Why?
|
| North Carolina | 3 | 2024 | 327 | 0.310 |
Why?
|
| Spinal Fusion | 2 | 2020 | 1310 | 0.300 |
Why?
|
| Motor Activity | 1 | 2018 | 2722 | 0.300 |
Why?
|
| Retrospective Studies | 41 | 2023 | 81835 | 0.300 |
Why?
|
| Bariatric Surgery | 1 | 2018 | 1007 | 0.300 |
Why?
|
| Community Health Services | 3 | 2024 | 659 | 0.300 |
Why?
|
| Reagent Kits, Diagnostic | 2 | 2011 | 239 | 0.300 |
Why?
|
| Adolescent | 40 | 2024 | 89163 | 0.300 |
Why?
|
| RNA, Viral | 18 | 2018 | 2854 | 0.300 |
Why?
|
| Hospitals, Special | 1 | 2008 | 90 | 0.290 |
Why?
|
| Quality Improvement | 4 | 2017 | 3858 | 0.290 |
Why?
|
| Follow-Up Studies | 21 | 2019 | 39429 | 0.290 |
Why?
|
| Reproducibility of Results | 21 | 2017 | 20232 | 0.290 |
Why?
|
| Guideline Adherence | 4 | 2018 | 2239 | 0.290 |
Why?
|
| Acquired Immunodeficiency Syndrome | 9 | 2014 | 2201 | 0.290 |
Why?
|
| Gastrectomy | 2 | 2023 | 696 | 0.290 |
Why?
|
| Young Adult | 33 | 2020 | 60038 | 0.290 |
Why?
|
| Drug Monitoring | 3 | 2018 | 964 | 0.290 |
Why?
|
| HLA Antigens | 2 | 2010 | 1333 | 0.290 |
Why?
|
| Delayed Diagnosis | 1 | 2011 | 469 | 0.290 |
Why?
|
| Markov Chains | 4 | 2018 | 977 | 0.280 |
Why?
|
| Chronic Disease | 7 | 2018 | 9379 | 0.280 |
Why?
|
| Cross-Sectional Studies | 26 | 2024 | 26348 | 0.280 |
Why?
|
| Treatment Failure | 11 | 2019 | 2655 | 0.280 |
Why?
|
| Risk | 10 | 2016 | 9642 | 0.280 |
Why?
|
| Clinical Protocols | 1 | 2013 | 1444 | 0.280 |
Why?
|
| Medical Records | 3 | 2013 | 1413 | 0.280 |
Why?
|
| Sex Distribution | 4 | 2016 | 2286 | 0.280 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2020 | 4403 | 0.280 |
Why?
|
| Radiography | 13 | 2016 | 6995 | 0.270 |
Why?
|
| Spondylolisthesis | 1 | 2008 | 173 | 0.270 |
Why?
|
| Risk Assessment | 14 | 2023 | 24310 | 0.270 |
Why?
|
| Reverse Transcriptase Inhibitors | 4 | 2009 | 622 | 0.270 |
Why?
|
| Osteoporosis | 6 | 2012 | 1606 | 0.270 |
Why?
|
| Lumbar Vertebrae | 3 | 2020 | 1885 | 0.270 |
Why?
|
| Vulnerable Populations | 2 | 2015 | 717 | 0.270 |
Why?
|
| Predictive Value of Tests | 15 | 2021 | 15459 | 0.270 |
Why?
|
| Diagnosis-Related Groups | 1 | 2008 | 448 | 0.270 |
Why?
|
| Automobile Driving | 1 | 2012 | 449 | 0.270 |
Why?
|
| Nigeria | 6 | 2020 | 777 | 0.270 |
Why?
|
| Nutrition Surveys | 3 | 2023 | 1734 | 0.260 |
Why?
|
| Patient Participation | 3 | 2017 | 1450 | 0.260 |
Why?
|
| Hernia, Ventral | 2 | 2021 | 220 | 0.260 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2006 | 130 | 0.260 |
Why?
|
| New Zealand | 2 | 2017 | 360 | 0.260 |
Why?
|
| Health Policy | 3 | 2013 | 2699 | 0.260 |
Why?
|
| Forecasting | 6 | 2020 | 2950 | 0.250 |
Why?
|
| Odds Ratio | 10 | 2017 | 9687 | 0.250 |
Why?
|
| Spinal Stenosis | 1 | 2008 | 261 | 0.250 |
Why?
|
| Models, Econometric | 4 | 2015 | 215 | 0.250 |
Why?
|
| Logistic Models | 13 | 2017 | 13323 | 0.250 |
Why?
|
| Office Visits | 1 | 2009 | 596 | 0.250 |
Why?
|
| Chemoprevention | 6 | 2012 | 326 | 0.250 |
Why?
|
| Developing Countries | 4 | 2019 | 2901 | 0.250 |
Why?
|
| Longevity | 1 | 2013 | 1078 | 0.250 |
Why?
|
| Perioperative Care | 3 | 2017 | 1046 | 0.250 |
Why?
|
| HIV Seropositivity | 4 | 2013 | 963 | 0.240 |
Why?
|
| Social Support | 5 | 2023 | 2195 | 0.240 |
Why?
|
| Confidence Intervals | 5 | 2011 | 2932 | 0.240 |
Why?
|
| Internet | 1 | 2017 | 3123 | 0.240 |
Why?
|
| Linear Models | 7 | 2019 | 5880 | 0.240 |
Why?
|
| Handwriting | 1 | 2004 | 26 | 0.240 |
Why?
|
| Accidental Falls | 3 | 2024 | 1081 | 0.230 |
Why?
|
| Blood Donors | 1 | 2006 | 345 | 0.230 |
Why?
|
| Survival Analysis | 13 | 2016 | 10127 | 0.230 |
Why?
|
| Health Care Surveys | 5 | 2017 | 2437 | 0.230 |
Why?
|
| Body Mass Index | 9 | 2024 | 13030 | 0.230 |
Why?
|
| Tuberculosis, Pulmonary | 3 | 2016 | 846 | 0.230 |
Why?
|
| Endrin | 1 | 2023 | 4 | 0.230 |
Why?
|
| Spinal Cord Compression | 2 | 2019 | 234 | 0.230 |
Why?
|
| Sick Leave | 1 | 2005 | 105 | 0.230 |
Why?
|
| Regression Analysis | 10 | 2016 | 6353 | 0.230 |
Why?
|
| Data Interpretation, Statistical | 4 | 2013 | 2705 | 0.230 |
Why?
|
| Postal Service | 1 | 2004 | 96 | 0.230 |
Why?
|
| Longitudinal Studies | 9 | 2021 | 14766 | 0.220 |
Why?
|
| Diet, Reducing | 2 | 2024 | 487 | 0.220 |
Why?
|
| Prognosis | 13 | 2023 | 30031 | 0.220 |
Why?
|
| Tibia | 5 | 2017 | 1075 | 0.220 |
Why?
|
| Lipopolysaccharides | 3 | 2016 | 2216 | 0.210 |
Why?
|
| Brazil | 3 | 2024 | 1247 | 0.210 |
Why?
|
| Prospective Studies | 29 | 2020 | 54913 | 0.210 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2013 | 1816 | 0.210 |
Why?
|
| Hip Dislocation | 2 | 2023 | 249 | 0.210 |
Why?
|
| Diphosphonates | 3 | 2014 | 635 | 0.210 |
Why?
|
| Walking | 4 | 2019 | 1202 | 0.210 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3240 | 0.210 |
Why?
|
| Patient-Centered Care | 2 | 2017 | 1439 | 0.210 |
Why?
|
| Haiti | 3 | 2019 | 553 | 0.210 |
Why?
|
| Guidelines as Topic | 4 | 2017 | 1395 | 0.210 |
Why?
|
| Forms and Records Control | 1 | 2003 | 158 | 0.200 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 3412 | 0.200 |
Why?
|
| Blood Loss, Surgical | 1 | 2006 | 643 | 0.200 |
Why?
|
| Sinusitis | 2 | 2021 | 995 | 0.200 |
Why?
|
| Smoking | 6 | 2021 | 9099 | 0.200 |
Why?
|
| Hospitalization | 6 | 2020 | 10845 | 0.200 |
Why?
|
| Socioeconomic Factors | 10 | 2019 | 7863 | 0.200 |
Why?
|
| Qualitative Research | 6 | 2022 | 3115 | 0.190 |
Why?
|
| Accidents, Traffic | 2 | 2017 | 821 | 0.190 |
Why?
|
| Leg | 3 | 2013 | 1089 | 0.190 |
Why?
|
| Hernia, Femoral | 1 | 2021 | 18 | 0.190 |
Why?
|
| Hip Joint | 5 | 2013 | 1018 | 0.180 |
Why?
|
| Primary Health Care | 4 | 2017 | 4736 | 0.180 |
Why?
|
| Residence Characteristics | 2 | 2012 | 2119 | 0.180 |
Why?
|
| Glucocorticoids | 3 | 2020 | 2170 | 0.180 |
Why?
|
| Anti-Infective Agents | 6 | 2009 | 986 | 0.180 |
Why?
|
| Reward | 2 | 2018 | 987 | 0.180 |
Why?
|
| Geography | 3 | 2013 | 654 | 0.180 |
Why?
|
| Telephone | 3 | 2013 | 630 | 0.180 |
Why?
|
| Diagnostic Tests, Routine | 4 | 2015 | 792 | 0.180 |
Why?
|
| Health Personnel | 3 | 2023 | 3384 | 0.180 |
Why?
|
| Massachusetts | 10 | 2020 | 8905 | 0.180 |
Why?
|
| Osteonecrosis | 2 | 2017 | 230 | 0.170 |
Why?
|
| Registries | 9 | 2022 | 8372 | 0.170 |
Why?
|
| Physicians | 4 | 2022 | 4615 | 0.170 |
Why?
|
| Drug Resistance, Multiple, Viral | 1 | 2020 | 52 | 0.170 |
Why?
|
| Drug Therapy, Combination | 10 | 2015 | 6320 | 0.170 |
Why?
|
| Biological Products | 2 | 2021 | 937 | 0.170 |
Why?
|
| Feasibility Studies | 4 | 2017 | 5308 | 0.170 |
Why?
|
| Refusal to Participate | 2 | 2013 | 30 | 0.170 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 2 | 2011 | 210 | 0.170 |
Why?
|
| Edema | 2 | 2019 | 766 | 0.170 |
Why?
|
| Home Care Services, Hospital-Based | 1 | 2019 | 45 | 0.170 |
Why?
|
| Hernia, Umbilical | 1 | 2021 | 102 | 0.170 |
Why?
|
| Disabled Persons | 4 | 2017 | 1218 | 0.170 |
Why?
|
| Bone Density Conservation Agents | 4 | 2011 | 797 | 0.160 |
Why?
|
| Case-Control Studies | 14 | 2023 | 22286 | 0.160 |
Why?
|
| Voluntary Programs | 3 | 2011 | 48 | 0.160 |
Why?
|
| Health Behavior | 3 | 2012 | 2649 | 0.160 |
Why?
|
| Consensus | 4 | 2024 | 3207 | 0.160 |
Why?
|
| Sexual Behavior | 6 | 2024 | 2200 | 0.160 |
Why?
|
| Hospitals, District | 1 | 2019 | 114 | 0.160 |
Why?
|
| Tenotomy | 1 | 2019 | 55 | 0.160 |
Why?
|
| Bone Diseases | 1 | 2022 | 418 | 0.160 |
Why?
|
| Joint Diseases | 3 | 2012 | 460 | 0.160 |
Why?
|
| Health Services Research | 3 | 2015 | 1815 | 0.160 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2023 | 530 | 0.160 |
Why?
|
| Social Conditions | 1 | 2019 | 121 | 0.150 |
Why?
|
| Drug Administration Schedule | 10 | 2019 | 4861 | 0.150 |
Why?
|
| Prosthesis Design | 2 | 2016 | 2126 | 0.150 |
Why?
|
| Ultrasonic Therapy | 1 | 2020 | 217 | 0.150 |
Why?
|
| Braces | 1 | 2019 | 139 | 0.150 |
Why?
|
| Algorithms | 8 | 2019 | 14157 | 0.150 |
Why?
|
| Masks | 1 | 2020 | 215 | 0.150 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2020 | 170 | 0.150 |
Why?
|
| Hernia, Inguinal | 1 | 2021 | 225 | 0.150 |
Why?
|
| Fractures, Spontaneous | 1 | 2019 | 232 | 0.150 |
Why?
|
| Patella | 2 | 2016 | 317 | 0.150 |
Why?
|
| Synovial Membrane | 2 | 2011 | 536 | 0.150 |
Why?
|
| Casts, Surgical | 1 | 2019 | 184 | 0.150 |
Why?
|
| Drug Prescriptions | 2 | 2019 | 1677 | 0.140 |
Why?
|
| Quality Assurance, Health Care | 1 | 2008 | 2179 | 0.140 |
Why?
|
| Child Restraint Systems | 1 | 2017 | 20 | 0.140 |
Why?
|
| Gait | 2 | 2024 | 822 | 0.140 |
Why?
|
| Sex Factors | 9 | 2016 | 10647 | 0.140 |
Why?
|
| Moving and Lifting Patients | 1 | 2017 | 18 | 0.140 |
Why?
|
| Preoperative Care | 4 | 2017 | 2257 | 0.140 |
Why?
|
| Quadriceps Muscle | 1 | 2018 | 157 | 0.140 |
Why?
|
| Lifting | 1 | 2017 | 55 | 0.140 |
Why?
|
| Focus Groups | 4 | 2022 | 1448 | 0.140 |
Why?
|
| Serologic Tests | 1 | 2019 | 383 | 0.140 |
Why?
|
| Intention to Treat Analysis | 2 | 2019 | 417 | 0.140 |
Why?
|
| Occupational Diseases | 1 | 2005 | 1494 | 0.130 |
Why?
|
| Proportional Hazards Models | 10 | 2020 | 12561 | 0.130 |
Why?
|
| Hallux Valgus | 1 | 2016 | 67 | 0.130 |
Why?
|
| Poisson Distribution | 3 | 2019 | 509 | 0.130 |
Why?
|
| Information Dissemination | 1 | 2024 | 1138 | 0.130 |
Why?
|
| Cross-Cultural Comparison | 1 | 2019 | 639 | 0.130 |
Why?
|
| HIV Reverse Transcriptase | 2 | 2009 | 212 | 0.130 |
Why?
|
| Femoral Fractures | 1 | 2019 | 376 | 0.130 |
Why?
|
| Housing | 1 | 2020 | 679 | 0.130 |
Why?
|
| Biometry | 1 | 1999 | 565 | 0.130 |
Why?
|
| Societies, Medical | 4 | 2017 | 3954 | 0.130 |
Why?
|
| Acupuncture Therapy | 1 | 2020 | 486 | 0.130 |
Why?
|
| Social Participation | 1 | 2017 | 185 | 0.130 |
Why?
|
| Monitoring, Ambulatory | 1 | 2019 | 357 | 0.130 |
Why?
|
| Foot Diseases | 1 | 2016 | 148 | 0.130 |
Why?
|
| Cause of Death | 1 | 2006 | 3727 | 0.120 |
Why?
|
| Mycoses | 4 | 2007 | 386 | 0.120 |
Why?
|
| Cryptococcus | 1 | 2015 | 28 | 0.120 |
Why?
|
| Treatment Refusal | 2 | 2011 | 432 | 0.120 |
Why?
|
| Drug Substitution | 1 | 2018 | 291 | 0.120 |
Why?
|
| Hospitals, Urban | 3 | 2012 | 501 | 0.120 |
Why?
|
| Hand | 2 | 2018 | 907 | 0.120 |
Why?
|
| Public Sector | 1 | 2017 | 265 | 0.120 |
Why?
|
| Naproxen | 1 | 2015 | 101 | 0.120 |
Why?
|
| Motor Vehicles | 1 | 2017 | 282 | 0.120 |
Why?
|
| Smoking Cessation | 2 | 2017 | 2078 | 0.120 |
Why?
|
| Sentinel Surveillance | 2 | 2007 | 292 | 0.120 |
Why?
|
| Antigens, Fungal | 1 | 2015 | 69 | 0.120 |
Why?
|
| Disease Transmission, Infectious | 2 | 2013 | 562 | 0.120 |
Why?
|
| Disabled Children | 1 | 2017 | 251 | 0.120 |
Why?
|
| Child Mortality | 1 | 2017 | 204 | 0.120 |
Why?
|
| Evidence-Based Medicine | 3 | 2019 | 3708 | 0.120 |
Why?
|
| Decision Making | 7 | 2022 | 3961 | 0.120 |
Why?
|
| Epidemics | 1 | 2020 | 517 | 0.120 |
Why?
|
| Watchful Waiting | 1 | 2019 | 496 | 0.120 |
Why?
|
| Athletic Injuries | 2 | 2019 | 1242 | 0.120 |
Why?
|
| Patient Transfer | 2 | 2019 | 796 | 0.120 |
Why?
|
| Self Administration | 1 | 2015 | 387 | 0.120 |
Why?
|
| Nonprescription Drugs | 1 | 2015 | 119 | 0.120 |
Why?
|
| Interviews as Topic | 5 | 2021 | 2733 | 0.120 |
Why?
|
| Observer Variation | 4 | 2016 | 2622 | 0.120 |
Why?
|
| Cryptococcosis | 1 | 2015 | 103 | 0.120 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2023 | 935 | 0.120 |
Why?
|
| Pilot Projects | 3 | 2019 | 8730 | 0.120 |
Why?
|
| Physician's Role | 2 | 2011 | 927 | 0.120 |
Why?
|
| Hypersensitivity | 1 | 2023 | 1172 | 0.120 |
Why?
|
| Patient Care Team | 3 | 2021 | 2526 | 0.120 |
Why?
|
| Injections, Subcutaneous | 1 | 2015 | 681 | 0.110 |
Why?
|
| Ibuprofen | 1 | 2015 | 229 | 0.110 |
Why?
|
| Nevirapine | 2 | 2015 | 273 | 0.110 |
Why?
|
| Length of Stay | 5 | 2024 | 6521 | 0.110 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 2 | 2012 | 938 | 0.110 |
Why?
|
| Pyrrolidinones | 1 | 2014 | 116 | 0.110 |
Why?
|
| Validation Studies as Topic | 2 | 2014 | 162 | 0.110 |
Why?
|
| Comparative Effectiveness Research | 1 | 2019 | 712 | 0.110 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 614 | 0.110 |
Why?
|
| Hydroxychloroquine | 1 | 2018 | 427 | 0.110 |
Why?
|
| Spinal Fractures | 2 | 2011 | 712 | 0.110 |
Why?
|
| Soft Tissue Injuries | 1 | 2015 | 173 | 0.110 |
Why?
|
| Infant | 11 | 2021 | 36496 | 0.110 |
Why?
|
| Surgical Procedures, Operative | 1 | 2005 | 1937 | 0.110 |
Why?
|
| Cardiovascular Diseases | 2 | 2017 | 15638 | 0.110 |
Why?
|
| Drug Utilization Review | 1 | 2014 | 248 | 0.110 |
Why?
|
| Femur | 3 | 2015 | 1311 | 0.110 |
Why?
|
| Shoulder Pain | 1 | 2014 | 152 | 0.110 |
Why?
|
| Physician Assistants | 1 | 2015 | 190 | 0.110 |
Why?
|
| Critical Pathways | 2 | 2010 | 476 | 0.110 |
Why?
|
| World Health Organization | 3 | 2014 | 1327 | 0.110 |
Why?
|
| Ritonavir | 2 | 2015 | 330 | 0.110 |
Why?
|
| Viremia | 1 | 2016 | 715 | 0.110 |
Why?
|
| Laser Therapy | 1 | 2020 | 1107 | 0.110 |
Why?
|
| Drug Hypersensitivity | 2 | 2020 | 922 | 0.110 |
Why?
|
| Educational Status | 4 | 2015 | 2519 | 0.110 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2015 | 1965 | 0.100 |
Why?
|
| HIV Seroprevalence | 2 | 2011 | 89 | 0.100 |
Why?
|
| Lower Extremity | 2 | 2018 | 1214 | 0.100 |
Why?
|
| Nurse Practitioners | 1 | 2015 | 271 | 0.100 |
Why?
|
| Australia | 1 | 2016 | 1264 | 0.100 |
Why?
|
| Attitude of Health Personnel | 3 | 2011 | 3922 | 0.100 |
Why?
|
| Education, Medical, Continuing | 1 | 2017 | 829 | 0.100 |
Why?
|
| India | 6 | 2018 | 2323 | 0.100 |
Why?
|
| Diazepam | 1 | 2013 | 215 | 0.100 |
Why?
|
| Allied Health Personnel | 1 | 2013 | 156 | 0.100 |
Why?
|
| Pulmonary Embolism | 4 | 2007 | 2591 | 0.100 |
Why?
|
| Child, Preschool | 11 | 2021 | 42620 | 0.100 |
Why?
|
| Decompression, Surgical | 2 | 2019 | 612 | 0.100 |
Why?
|
| Patient Care Planning | 1 | 2017 | 904 | 0.100 |
Why?
|
| Tendinopathy | 1 | 2014 | 176 | 0.100 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 1795 | 0.100 |
Why?
|
| Clinical Competence | 3 | 2017 | 4841 | 0.090 |
Why?
|
| Electronic Health Records | 2 | 2022 | 4877 | 0.090 |
Why?
|
| Public Health | 2 | 2020 | 2693 | 0.090 |
Why?
|
| Adrenal Insufficiency | 1 | 2013 | 194 | 0.090 |
Why?
|
| Needs Assessment | 1 | 2017 | 1146 | 0.090 |
Why?
|
| Midazolam | 1 | 2013 | 267 | 0.090 |
Why?
|
| Odontoid Process | 1 | 2011 | 46 | 0.090 |
Why?
|
| Adenine | 3 | 2012 | 993 | 0.090 |
Why?
|
| Sputum | 4 | 2016 | 511 | 0.090 |
Why?
|
| Remission Induction | 2 | 2015 | 2408 | 0.090 |
Why?
|
| Infusions, Intravenous | 1 | 2015 | 2228 | 0.090 |
Why?
|
| National Institutes of Health (U.S.) | 3 | 2022 | 794 | 0.090 |
Why?
|
| HIV Protease | 1 | 2011 | 98 | 0.090 |
Why?
|
| Bone Cements | 1 | 2012 | 326 | 0.090 |
Why?
|
| Specialization | 1 | 2015 | 782 | 0.090 |
Why?
|
| Transportation of Patients | 1 | 2012 | 176 | 0.090 |
Why?
|
| Adrenal Glands | 1 | 2013 | 557 | 0.090 |
Why?
|
| Cartilage | 1 | 2014 | 808 | 0.090 |
Why?
|
| Femoracetabular Impingement | 1 | 2013 | 180 | 0.090 |
Why?
|
| Pituitary Gland | 1 | 2013 | 634 | 0.090 |
Why?
|
| Drug Utilization | 2 | 2020 | 1192 | 0.090 |
Why?
|
| Infant, Newborn | 7 | 2021 | 26394 | 0.090 |
Why?
|
| Self Efficacy | 2 | 2013 | 651 | 0.090 |
Why?
|
| Teratogens | 1 | 2011 | 117 | 0.090 |
Why?
|
| Genotype | 8 | 2012 | 13045 | 0.090 |
Why?
|
| Family Characteristics | 1 | 2015 | 1001 | 0.090 |
Why?
|
| Computers | 2 | 2010 | 592 | 0.090 |
Why?
|
| Proton Pump Inhibitors | 1 | 2015 | 552 | 0.090 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 2103 | 0.090 |
Why?
|
| Orthotic Devices | 1 | 2011 | 131 | 0.090 |
Why?
|
| Environment, Controlled | 2 | 2007 | 42 | 0.090 |
Why?
|
| Outpatients | 3 | 2014 | 1607 | 0.090 |
Why?
|
| Information Seeking Behavior | 1 | 2011 | 116 | 0.080 |
Why?
|
| Drug Administration Routes | 1 | 2010 | 151 | 0.080 |
Why?
|
| CD4-CD8 Ratio | 1 | 2009 | 114 | 0.080 |
Why?
|
| Osteotomy | 1 | 2015 | 838 | 0.080 |
Why?
|
| Databases, Factual | 4 | 2022 | 8081 | 0.080 |
Why?
|
| Anesthetics, Intravenous | 1 | 2013 | 396 | 0.080 |
Why?
|
| Cultural Characteristics | 1 | 2011 | 250 | 0.080 |
Why?
|
| Likelihood Functions | 1 | 2013 | 993 | 0.080 |
Why?
|
| Cost Savings | 1 | 2015 | 917 | 0.080 |
Why?
|
| Bacterial Infections | 3 | 2007 | 1397 | 0.080 |
Why?
|
| Sample Size | 1 | 2013 | 851 | 0.080 |
Why?
|
| Sampling Studies | 1 | 2011 | 617 | 0.080 |
Why?
|
| Assisted Living Facilities | 1 | 2009 | 27 | 0.080 |
Why?
|
| Bacteriological Techniques | 1 | 2010 | 277 | 0.080 |
Why?
|
| Joints | 1 | 2011 | 324 | 0.080 |
Why?
|
| Medicare Part B | 1 | 2010 | 117 | 0.080 |
Why?
|
| Benzoxazines | 1 | 2011 | 321 | 0.080 |
Why?
|
| Research Support as Topic | 1 | 2013 | 699 | 0.080 |
Why?
|
| Ganciclovir | 2 | 2001 | 255 | 0.080 |
Why?
|
| Europe | 1 | 2016 | 3439 | 0.080 |
Why?
|
| Secondary Prevention | 2 | 2012 | 1479 | 0.080 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2014 | 470 | 0.080 |
Why?
|
| Recurrence | 2 | 2019 | 8510 | 0.080 |
Why?
|
| Selection Bias | 1 | 2010 | 360 | 0.080 |
Why?
|
| France | 5 | 2012 | 495 | 0.080 |
Why?
|
| HIV Fusion Inhibitors | 2 | 2006 | 83 | 0.080 |
Why?
|
| Government Programs | 2 | 2007 | 278 | 0.080 |
Why?
|
| Body Size | 1 | 2011 | 463 | 0.080 |
Why?
|
| Protease Inhibitors | 1 | 2012 | 753 | 0.080 |
Why?
|
| Malawi | 2 | 2019 | 308 | 0.080 |
Why?
|
| Pyrimidinones | 1 | 2011 | 387 | 0.080 |
Why?
|
| Toxoplasmosis | 2 | 2007 | 94 | 0.080 |
Why?
|
| Medical Record Linkage | 1 | 2010 | 286 | 0.080 |
Why?
|
| Mycobacterium Infections | 2 | 2006 | 122 | 0.080 |
Why?
|
| Hypothalamus | 1 | 2013 | 1004 | 0.070 |
Why?
|
| Hepatitis C, Chronic | 1 | 2016 | 1031 | 0.070 |
Why?
|
| Carcinoma | 1 | 2019 | 2341 | 0.070 |
Why?
|
| Melanoma | 1 | 2007 | 5740 | 0.070 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2011 | 341 | 0.070 |
Why?
|
| Resource Allocation | 2 | 2009 | 353 | 0.070 |
Why?
|
| Mortality | 4 | 2019 | 2917 | 0.070 |
Why?
|
| HIV-2 | 1 | 2008 | 156 | 0.070 |
Why?
|
| Pennsylvania | 2 | 2010 | 616 | 0.070 |
Why?
|
| Jamaica | 1 | 2007 | 54 | 0.070 |
Why?
|
| Inpatients | 4 | 2020 | 2561 | 0.070 |
Why?
|
| Emigrants and Immigrants | 1 | 2014 | 548 | 0.070 |
Why?
|
| Medicine | 2 | 2021 | 946 | 0.070 |
Why?
|
| Caribbean Region | 1 | 2007 | 193 | 0.070 |
Why?
|
| Population Surveillance | 2 | 2009 | 2601 | 0.070 |
Why?
|
| Mass Spectrometry | 1 | 2014 | 2204 | 0.070 |
Why?
|
| HLA-B Antigens | 1 | 2008 | 319 | 0.070 |
Why?
|
| Organizational Culture | 1 | 2011 | 510 | 0.070 |
Why?
|
| Skin Neoplasms | 1 | 2007 | 5891 | 0.070 |
Why?
|
| Synovial Fluid | 2 | 2023 | 393 | 0.070 |
Why?
|
| Medical Informatics | 1 | 2014 | 737 | 0.070 |
Why?
|
| Soccer | 1 | 2009 | 142 | 0.070 |
Why?
|
| Health Services Needs and Demand | 1 | 2015 | 1408 | 0.070 |
Why?
|
| HIV Long-Term Survivors | 1 | 2007 | 121 | 0.070 |
Why?
|
| Femoral Neck Fractures | 1 | 2008 | 143 | 0.070 |
Why?
|
| Urban Population | 4 | 2012 | 2047 | 0.070 |
Why?
|
| HIV Envelope Protein gp41 | 2 | 2006 | 304 | 0.070 |
Why?
|
| Fluoroscopy | 1 | 2011 | 952 | 0.070 |
Why?
|
| Malaria | 2 | 2007 | 1240 | 0.070 |
Why?
|
| Toxoplasmosis, Cerebral | 1 | 2006 | 19 | 0.070 |
Why?
|
| Topography, Medical | 1 | 2006 | 37 | 0.070 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2012 | 1794 | 0.070 |
Why?
|
| Body Height | 1 | 2012 | 1568 | 0.070 |
Why?
|
| Urban Health | 2 | 2024 | 535 | 0.070 |
Why?
|
| Public Policy | 1 | 2010 | 560 | 0.070 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2011 | 1359 | 0.070 |
Why?
|
| Interleukin-10 | 1 | 2011 | 1184 | 0.070 |
Why?
|
| Virus Replication | 2 | 2011 | 2443 | 0.060 |
Why?
|
| Regional Health Planning | 1 | 2006 | 96 | 0.060 |
Why?
|
| Insurance Claim Review | 1 | 2010 | 745 | 0.060 |
Why?
|
| Prostheses and Implants | 1 | 2013 | 1279 | 0.060 |
Why?
|
| Spondylitis, Ankylosing | 2 | 2017 | 160 | 0.060 |
Why?
|
| Surgical Wound Infection | 2 | 2007 | 1544 | 0.060 |
Why?
|
| Probability | 1 | 2011 | 2483 | 0.060 |
Why?
|
| Air Microbiology | 1 | 2005 | 95 | 0.060 |
Why?
|
| Bandages | 1 | 2007 | 273 | 0.060 |
Why?
|
| Statistics, Nonparametric | 4 | 2016 | 2861 | 0.060 |
Why?
|
| Pediatrics | 2 | 2017 | 3622 | 0.060 |
Why?
|
| Informed Consent | 1 | 2011 | 1012 | 0.060 |
Why?
|
| Zygapophyseal Joint | 1 | 2006 | 128 | 0.060 |
Why?
|
| Quality of Health Care | 3 | 2016 | 4340 | 0.060 |
Why?
|
| Bisexuality | 2 | 1997 | 294 | 0.060 |
Why?
|
| Colonoscopy | 1 | 2013 | 1412 | 0.060 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2011 | 1786 | 0.060 |
Why?
|
| Colorado | 1 | 2004 | 166 | 0.060 |
Why?
|
| Cytomegalovirus Infections | 3 | 2001 | 838 | 0.060 |
Why?
|
| Proteome | 1 | 2014 | 1881 | 0.060 |
Why?
|
| Sulfonamides | 1 | 2014 | 1988 | 0.060 |
Why?
|
| Population | 1 | 2004 | 141 | 0.060 |
Why?
|
| Arthritis, Psoriatic | 2 | 2017 | 220 | 0.060 |
Why?
|
| Fracture Fixation, Internal | 2 | 2008 | 981 | 0.060 |
Why?
|
| Asthma | 1 | 2023 | 6274 | 0.060 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2006 | 219 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 4213 | 0.060 |
Why?
|
| Psychotherapy | 1 | 2013 | 1656 | 0.060 |
Why?
|
| Leptin | 1 | 2012 | 1598 | 0.060 |
Why?
|
| Lung Neoplasms | 2 | 2019 | 13589 | 0.060 |
Why?
|
| Muscle, Skeletal | 1 | 2019 | 4984 | 0.060 |
Why?
|
| Chicago | 1 | 2024 | 255 | 0.060 |
Why?
|
| Ohio | 1 | 2004 | 328 | 0.060 |
Why?
|
| Referral and Consultation | 3 | 2012 | 3629 | 0.060 |
Why?
|
| Public Health Administration | 1 | 2006 | 242 | 0.060 |
Why?
|
| Mental Health | 2 | 2015 | 3271 | 0.060 |
Why?
|
| Review Literature as Topic | 1 | 2006 | 354 | 0.050 |
Why?
|
| Africa South of the Sahara | 3 | 2014 | 750 | 0.050 |
Why?
|
| Cervical Vertebrae | 1 | 2010 | 982 | 0.050 |
Why?
|
| Spinal Cord | 1 | 2012 | 1814 | 0.050 |
Why?
|
| Chi-Square Distribution | 3 | 2019 | 3438 | 0.050 |
Why?
|
| Bone Density | 1 | 2016 | 3561 | 0.050 |
Why?
|
| Child | 12 | 2021 | 80856 | 0.050 |
Why?
|
| Dideoxynucleosides | 2 | 2017 | 135 | 0.050 |
Why?
|
| Bayes Theorem | 3 | 2020 | 2359 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2011 | 1669 | 0.050 |
Why?
|
| Rural Health | 1 | 2024 | 300 | 0.050 |
Why?
|
| Rehabilitation Centers | 1 | 2004 | 250 | 0.050 |
Why?
|
| Pneumonia, Pneumocystis | 2 | 2002 | 242 | 0.050 |
Why?
|
| Bone Screws | 1 | 2006 | 534 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 9261 | 0.050 |
Why?
|
| Intraoperative Care | 1 | 2006 | 772 | 0.050 |
Why?
|
| Cluster Analysis | 3 | 2019 | 2730 | 0.050 |
Why?
|
| Siblings | 1 | 2007 | 829 | 0.050 |
Why?
|
| Femur Head Necrosis | 1 | 2003 | 133 | 0.050 |
Why?
|
| Financing, Government | 1 | 2006 | 473 | 0.050 |
Why?
|
| Pentamidine | 1 | 2002 | 44 | 0.050 |
Why?
|
| Ethambutol | 2 | 2012 | 59 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2007 | 1196 | 0.050 |
Why?
|
| Dapsone | 1 | 2002 | 56 | 0.050 |
Why?
|
| Drug Discovery | 1 | 2010 | 1062 | 0.050 |
Why?
|
| Naphthoquinones | 1 | 2002 | 59 | 0.050 |
Why?
|
| Quality Indicators, Health Care | 3 | 2017 | 1813 | 0.050 |
Why?
|
| Morbidity | 1 | 2007 | 1760 | 0.050 |
Why?
|
| Body Weight | 1 | 2012 | 4630 | 0.050 |
Why?
|
| Occupational Therapy | 1 | 2023 | 142 | 0.050 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 2 | 1999 | 76 | 0.050 |
Why?
|
| Budgets | 2 | 2020 | 232 | 0.050 |
Why?
|
| Antiprotozoal Agents | 1 | 2002 | 95 | 0.050 |
Why?
|
| Alleles | 2 | 2010 | 6880 | 0.050 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 3407 | 0.050 |
Why?
|
| Statistics as Topic | 1 | 2008 | 2362 | 0.050 |
Why?
|
| Physician-Patient Relations | 2 | 2013 | 3267 | 0.050 |
Why?
|
| Preventive Health Services | 1 | 2006 | 568 | 0.050 |
Why?
|
| Antibodies, Heterophile | 1 | 2001 | 128 | 0.050 |
Why?
|
| Rheumatoid Factor | 1 | 2021 | 184 | 0.050 |
Why?
|
| Infectious Mononucleosis | 1 | 2001 | 133 | 0.050 |
Why?
|
| Organ Size | 2 | 2016 | 2268 | 0.050 |
Why?
|
| Pyrroles | 2 | 2017 | 1127 | 0.050 |
Why?
|
| Proteomics | 1 | 2014 | 3901 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 8751 | 0.040 |
Why?
|
| Wrist Joint | 2 | 2014 | 267 | 0.040 |
Why?
|
| Isoniazid | 2 | 2012 | 288 | 0.040 |
Why?
|
| Arthroplasty | 1 | 2023 | 310 | 0.040 |
Why?
|
| Groin | 1 | 2021 | 107 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2013 | 2513 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2006 | 1532 | 0.040 |
Why?
|
| Operating Rooms | 1 | 2007 | 799 | 0.040 |
Why?
|
| Health Status Indicators | 2 | 2004 | 971 | 0.040 |
Why?
|
| Self Care | 2 | 2017 | 798 | 0.040 |
Why?
|
| Bone Marrow | 3 | 2016 | 2929 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2011 | 2664 | 0.040 |
Why?
|
| Epidemiologic Methods | 1 | 2005 | 1337 | 0.040 |
Why?
|
| Academic Medical Centers | 3 | 2016 | 2785 | 0.040 |
Why?
|
| Neurosurgical Procedures | 1 | 2011 | 2096 | 0.040 |
Why?
|
| Hepatitis C | 1 | 2010 | 1594 | 0.040 |
Why?
|
| Diaphyses | 1 | 2019 | 65 | 0.040 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2020 | 162 | 0.040 |
Why?
|
| Fees and Charges | 1 | 2020 | 192 | 0.040 |
Why?
|
| Abdominal Wall | 1 | 2021 | 167 | 0.040 |
Why?
|
| Arthritis | 1 | 2004 | 685 | 0.040 |
Why?
|
| Musculoskeletal Manipulations | 1 | 2018 | 24 | 0.040 |
Why?
|
| Patient Discharge | 2 | 2019 | 3471 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2023 | 1604 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 2 | 2018 | 1727 | 0.040 |
Why?
|
| Pelvis | 1 | 2023 | 737 | 0.040 |
Why?
|
| Piperidines | 2 | 2017 | 1664 | 0.040 |
Why?
|
| Warfarin | 1 | 2007 | 1493 | 0.040 |
Why?
|
| Infection Control | 1 | 2005 | 985 | 0.040 |
Why?
|
| Patient Dropouts | 1 | 2020 | 411 | 0.040 |
Why?
|
| After-Hours Care | 1 | 2019 | 102 | 0.040 |
Why?
|
| Home Care Services | 1 | 2004 | 655 | 0.040 |
Why?
|
| Attitude to Health | 2 | 2005 | 2030 | 0.040 |
Why?
|
| Arthrodesis | 1 | 2019 | 186 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2019 | 791 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 2007 | 1317 | 0.040 |
Why?
|
| Antiviral Agents | 2 | 2001 | 3062 | 0.030 |
Why?
|
| Mental Disorders | 2 | 2015 | 6879 | 0.030 |
Why?
|
| Computational Biology | 1 | 2009 | 3549 | 0.030 |
Why?
|
| Platelet Count | 1 | 2019 | 786 | 0.030 |
Why?
|
| Single-Blind Method | 2 | 2012 | 1585 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 13709 | 0.030 |
Why?
|
| Postpartum Period | 1 | 2023 | 1197 | 0.030 |
Why?
|
| HIV Antibodies | 3 | 2012 | 1335 | 0.030 |
Why?
|
| Spondylarthritis | 1 | 2017 | 62 | 0.030 |
Why?
|
| Resistance Training | 1 | 2018 | 199 | 0.030 |
Why?
|
| Survival Rate | 3 | 2018 | 12875 | 0.030 |
Why?
|
| Specialties, Surgical | 1 | 2021 | 393 | 0.030 |
Why?
|
| Peptide Fragments | 2 | 2006 | 5151 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2001 | 841 | 0.030 |
Why?
|
| Pregnancy | 5 | 2023 | 30179 | 0.030 |
Why?
|
| Lamivudine | 1 | 2017 | 368 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2009 | 4613 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2008 | 3586 | 0.030 |
Why?
|
| Keratan Sulfate | 1 | 2014 | 17 | 0.030 |
Why?
|
| Random Allocation | 1 | 2019 | 2399 | 0.030 |
Why?
|
| Pyrimidines | 2 | 2017 | 3050 | 0.030 |
Why?
|
| Mozambique | 1 | 2014 | 55 | 0.030 |
Why?
|
| Poverty | 1 | 2006 | 2719 | 0.030 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2017 | 2173 | 0.030 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2015 | 123 | 0.030 |
Why?
|
| Africa, Eastern | 1 | 2014 | 76 | 0.030 |
Why?
|
| Netherlands | 1 | 2019 | 2274 | 0.030 |
Why?
|
| Clusterin | 1 | 2014 | 72 | 0.030 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2014 | 142 | 0.030 |
Why?
|
| Patellofemoral Joint | 1 | 2016 | 133 | 0.030 |
Why?
|
| Direct Service Costs | 2 | 2006 | 61 | 0.030 |
Why?
|
| Child Abuse, Sexual | 1 | 1997 | 404 | 0.030 |
Why?
|
| Portugal | 1 | 2013 | 91 | 0.030 |
Why?
|
| Income | 2 | 2013 | 1878 | 0.030 |
Why?
|
| Cholesterol | 1 | 2002 | 2910 | 0.030 |
Why?
|
| Minority Groups | 2 | 2012 | 1215 | 0.030 |
Why?
|
| Gross Domestic Product | 1 | 2013 | 77 | 0.030 |
Why?
|
| Caregivers | 2 | 2017 | 2302 | 0.030 |
Why?
|
| Streptomycin | 1 | 2012 | 69 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2024 | 1876 | 0.030 |
Why?
|
| Kanamycin | 1 | 2012 | 63 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2017 | 876 | 0.030 |
Why?
|
| Safety | 1 | 2017 | 1159 | 0.030 |
Why?
|
| Patients | 1 | 1999 | 909 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2017 | 778 | 0.030 |
Why?
|
| Family | 1 | 2023 | 3208 | 0.020 |
Why?
|
| Antitubercular Agents | 2 | 2011 | 1390 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2019 | 21157 | 0.020 |
Why?
|
| Hearing Disorders | 1 | 2012 | 126 | 0.020 |
Why?
|
| Hip | 1 | 2013 | 255 | 0.020 |
Why?
|
| Heterosexuality | 1 | 2014 | 309 | 0.020 |
Why?
|
| Delirium | 1 | 2024 | 1694 | 0.020 |
Why?
|
| Automation | 1 | 2014 | 588 | 0.020 |
Why?
|
| Urinalysis | 1 | 2014 | 369 | 0.020 |
Why?
|
| Ontario | 1 | 2012 | 403 | 0.020 |
Why?
|
| Calibration | 1 | 2014 | 823 | 0.020 |
Why?
|
| International Classification of Diseases | 1 | 2017 | 925 | 0.020 |
Why?
|
| Africa | 1 | 2013 | 726 | 0.020 |
Why?
|
| General Surgery | 1 | 2003 | 1714 | 0.020 |
Why?
|
| Atlanto-Axial Joint | 1 | 2011 | 60 | 0.020 |
Why?
|
| Hospitals, Rural | 1 | 2012 | 176 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2017 | 2079 | 0.020 |
Why?
|
| State Government | 2 | 2006 | 389 | 0.020 |
Why?
|
| Urban Health Services | 1 | 2012 | 177 | 0.020 |
Why?
|
| Directly Observed Therapy | 1 | 2011 | 139 | 0.020 |
Why?
|
| Rotator Cuff | 1 | 2014 | 349 | 0.020 |
Why?
|
| Stereotyping | 1 | 2012 | 243 | 0.020 |
Why?
|
| Sickness Impact Profile | 1 | 2012 | 299 | 0.020 |
Why?
|
| Reference Standards | 1 | 2014 | 1015 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 2010 | 0.020 |
Why?
|
| Kinetics | 1 | 2018 | 6347 | 0.020 |
Why?
|
| District of Columbia | 1 | 2010 | 159 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 3813 | 0.020 |
Why?
|
| Lymphoma | 1 | 2019 | 1907 | 0.020 |
Why?
|
| Program Development | 1 | 2016 | 1296 | 0.020 |
Why?
|
| Weight-Bearing | 1 | 2013 | 533 | 0.020 |
Why?
|
| Rifampin | 1 | 2012 | 345 | 0.020 |
Why?
|
| Tendon Injuries | 1 | 2014 | 329 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2019 | 1802 | 0.020 |
Why?
|
| Data Collection | 3 | 2011 | 3329 | 0.020 |
Why?
|
| AIDS Vaccines | 1 | 1996 | 896 | 0.020 |
Why?
|
| Health Care Rationing | 2 | 2007 | 436 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2017 | 1514 | 0.020 |
Why?
|
| Alkynes | 1 | 2011 | 327 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2011 | 575 | 0.020 |
Why?
|
| Fecal Incontinence | 1 | 2012 | 242 | 0.020 |
Why?
|
| Ethics, Research | 1 | 2011 | 177 | 0.020 |
Why?
|
| Public Assistance | 1 | 2009 | 47 | 0.020 |
Why?
|
| Empirical Research | 1 | 2009 | 120 | 0.020 |
Why?
|
| Cyclopropanes | 1 | 2011 | 437 | 0.020 |
Why?
|
| Sexual Partners | 1 | 2014 | 806 | 0.020 |
Why?
|
| Joint Instability | 1 | 2016 | 802 | 0.020 |
Why?
|
| Data Mining | 1 | 2014 | 561 | 0.020 |
Why?
|
| Sclerosis | 1 | 2009 | 213 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2016 | 1226 | 0.020 |
Why?
|
| Drug and Narcotic Control | 1 | 2010 | 146 | 0.020 |
Why?
|
| Latent Tuberculosis | 1 | 2012 | 224 | 0.020 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2011 | 2181 | 0.020 |
Why?
|
| Developed Countries | 1 | 2012 | 451 | 0.020 |
Why?
|
| Cell Count | 1 | 2013 | 1834 | 0.020 |
Why?
|
| Programming Languages | 1 | 2009 | 130 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 2477 | 0.020 |
Why?
|
| Prejudice | 1 | 2012 | 574 | 0.020 |
Why?
|
| ROC Curve | 1 | 2016 | 3623 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 4931 | 0.020 |
Why?
|
| Homosexuality | 1 | 2009 | 268 | 0.020 |
Why?
|
| Models, Immunological | 1 | 2010 | 516 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2013 | 810 | 0.020 |
Why?
|
| Urinary Incontinence | 1 | 2012 | 494 | 0.020 |
Why?
|
| Rural Health Services | 1 | 2012 | 392 | 0.020 |
Why?
|
| Saliva | 1 | 2012 | 854 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2011 | 17637 | 0.020 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2012 | 590 | 0.020 |
Why?
|
| Software | 2 | 2014 | 4465 | 0.020 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2008 | 119 | 0.020 |
Why?
|
| Health Expenditures | 1 | 2020 | 2391 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 1706 | 0.020 |
Why?
|
| Postural Balance | 1 | 2012 | 638 | 0.020 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2008 | 67 | 0.020 |
Why?
|
| Learning | 1 | 2017 | 1762 | 0.020 |
Why?
|
| State Health Plans | 1 | 2009 | 220 | 0.020 |
Why?
|
| Decision Trees | 1 | 2009 | 510 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 749 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 10784 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2010 | 6087 | 0.020 |
Why?
|
| Virulence | 1 | 2011 | 1301 | 0.020 |
Why?
|
| Shoulder Joint | 1 | 2014 | 749 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 1892 | 0.020 |
Why?
|
| Health Facility Size | 1 | 2006 | 61 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2014 | 2207 | 0.020 |
Why?
|
| Models, Organizational | 1 | 2010 | 546 | 0.020 |
Why?
|
| Fee-for-Service Plans | 1 | 2012 | 714 | 0.020 |
Why?
|
| Hip Prosthesis | 1 | 2012 | 924 | 0.020 |
Why?
|
| Remote Consultation | 1 | 2009 | 242 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2010 | 1083 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2014 | 1602 | 0.020 |
Why?
|
| DNA Primers | 1 | 2010 | 2825 | 0.020 |
Why?
|
| Internal Fixators | 1 | 2006 | 184 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 2010 | 1474 | 0.020 |
Why?
|
| Protective Clothing | 1 | 2005 | 103 | 0.020 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2007 | 395 | 0.020 |
Why?
|
| Microscopy | 1 | 2010 | 909 | 0.020 |
Why?
|
| Candidiasis | 1 | 2008 | 367 | 0.020 |
Why?
|
| Life Style | 1 | 2017 | 3929 | 0.020 |
Why?
|
| Memory Disorders | 1 | 2012 | 1204 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 6242 | 0.020 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 2411 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2011 | 1670 | 0.020 |
Why?
|
| Vision Disorders | 1 | 2012 | 1092 | 0.020 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2006 | 211 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2010 | 2072 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 4582 | 0.010 |
Why?
|
| Language | 1 | 2014 | 1557 | 0.010 |
Why?
|
| Virology | 1 | 2005 | 76 | 0.010 |
Why?
|
| Pharmacogenetics | 1 | 2008 | 677 | 0.010 |
Why?
|
| Prosthesis-Related Infections | 1 | 2010 | 491 | 0.010 |
Why?
|
| Deoxycytidine | 1 | 2009 | 888 | 0.010 |
Why?
|
| Federal Government | 1 | 2006 | 266 | 0.010 |
Why?
|
| Social Stigma | 1 | 2011 | 785 | 0.010 |
Why?
|
| Sequence Analysis, RNA | 1 | 2012 | 2038 | 0.010 |
Why?
|
| Epitopes | 1 | 2010 | 2523 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 4362 | 0.010 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2011 | 1061 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2008 | 1742 | 0.010 |
Why?
|
| Pressure | 1 | 2007 | 1173 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2010 | 2203 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2011 | 5042 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2013 | 6035 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2011 | 3164 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 20763 | 0.010 |
Why?
|
| Inflammation | 1 | 2023 | 10863 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 13447 | 0.010 |
Why?
|
| Parasitic Diseases | 1 | 2003 | 76 | 0.010 |
Why?
|
| Psychology | 1 | 2004 | 356 | 0.010 |
Why?
|
| Peptides | 1 | 2014 | 4368 | 0.010 |
Why?
|
| Atovaquone | 1 | 2002 | 56 | 0.010 |
Why?
|
| Body Constitution | 1 | 2002 | 273 | 0.010 |
Why?
|
| Appointments and Schedules | 1 | 2006 | 443 | 0.010 |
Why?
|
| Phenotype | 1 | 2020 | 16712 | 0.010 |
Why?
|
| Rural Population | 1 | 2012 | 2317 | 0.010 |
Why?
|
| Multiple Myeloma | 1 | 2019 | 5193 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2012 | 5893 | 0.010 |
Why?
|
| Mutation | 3 | 2010 | 30235 | 0.010 |
Why?
|
| Value of Life | 1 | 2001 | 98 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 5709 | 0.010 |
Why?
|
| Workload | 1 | 2006 | 852 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 2005 | 1100 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 4247 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2011 | 5803 | 0.010 |
Why?
|
| Patient Simulation | 1 | 2002 | 297 | 0.010 |
Why?
|
| Florida | 1 | 2001 | 430 | 0.010 |
Why?
|
| Acute Disease | 1 | 2011 | 7245 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 2011 | 2959 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 4774 | 0.010 |
Why?
|
| Base Sequence | 1 | 2010 | 12426 | 0.010 |
Why?
|
| New York | 1 | 2001 | 881 | 0.010 |
Why?
|
| Rifabutin | 1 | 1999 | 59 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2001 | 962 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2008 | 2590 | 0.010 |
Why?
|
| Clarithromycin | 1 | 1999 | 87 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2010 | 3210 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 2001 | 829 | 0.010 |
Why?
|
| Arm | 1 | 2001 | 590 | 0.010 |
Why?
|
| Azithromycin | 1 | 1999 | 200 | 0.010 |
Why?
|
| Hospitals, Teaching | 1 | 2002 | 1158 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2017 | 5952 | 0.010 |
Why?
|
| Geriatric Assessment | 1 | 2004 | 1422 | 0.010 |
Why?
|
| Hospital Costs | 1 | 2003 | 959 | 0.010 |
Why?
|
| Cytomegalovirus | 1 | 2001 | 755 | 0.010 |
Why?
|
| Cell Line | 1 | 2010 | 15610 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 1 | 2001 | 1081 | 0.010 |
Why?
|
| Movement | 1 | 2001 | 1489 | 0.010 |
Why?
|
| Body Composition | 1 | 2002 | 2455 | 0.010 |
Why?
|
| Radiology | 1 | 2006 | 2118 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 16023 | 0.010 |
Why?
|
| Peer Group | 1 | 1996 | 697 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 2002 | 3335 | 0.010 |
Why?
|
| Medicaid | 1 | 2001 | 2843 | 0.000 |
Why?
|
| Hospital Mortality | 1 | 2001 | 5371 | 0.000 |
Why?
|